Skip to main content

Table 1 Patients’ and treatment characteristics at the ECMO connection (n = 91)

From: Gastrointestinal colonization with multidrug-resistant Gram-negative bacteria during extracorporeal membrane oxygenation: effect on the risk of subsequent infections and impact on patient outcome

Patients’ characteristicsSubgroupsFrequency or median
Age (years) 48.5 (37–56)
Gender (male) 58 (63%)
Weight (kg) 70 (65–85)
Charlson Comorbidity Index 1 (0–3)
Major comorbiditiesActive smoker26 (28%)
Immunomodulating therapiesa22 (24%)
Hematologic malignancies13 (14%)
COPD10 (11%)
Hepatopathy10 (11%)
Coronary artery disease9 (10%)
Diabetes7 (8%)
AIDS3 (3%)
Transferred from peripheral hospital 76 (82%)
Transferred while on ECMO support 58 (63%)
Diagnosis and admissionARDS72 (78%)
Cardiogenic shock6 (7%)
Asthma4 (4%)
COPD exacerbation4 (4%)
Septic shock4 (4%)
Other2 (2%)
Infection at admission 65 (71%)
Autoimmune disease 8 (9%)
SAPS II 37 (32–47)
SOFA score 8 (6–11)
PaO2/FiO2 < 100 mmHg 70 (76%)
ECMO duration (days) 14 (8–27)
Veno-venous ECMO 80 (87%)
Low flow ECCO2R 8 (9%)
Femo-femoral cannulation 76 (83%)
ECMO circuits 2 (1–4)
IMV duration (days) 25 (12–44)
IMV duration prior to ECMO connection (days) 2 (1–6)
RRT during ECMO course 33 (36%)
RRT prior to ECMO connection 15 (16%)
  1. Data are presented as absolute frequency (% of the included patients) or as median and interquartile range
  2. ECMO extracorporeal membrane oxygenation, COPD chronic obstructive pulmonary disease, ARDS acute respiratory distress syndrome, SAPS II simplified acute physiology score, SOFA sequential organ failure assessment, ECCO2R extracorporeal carbon dioxide removal, AIDS acquired immunodeficiency syndrome, IMV invasive mechanical ventilation, RRT renal replacement therapy
  3. aIncluding high-dosage corticosteroids, immunosuppressants or both